Addition of triple negativity of breast cancer as an indicator for germline mutations in predisposing genes increases sensitivity of clinical selection criteria

Additional capecitabine use in early-stage triple negative breast cancer patients receiving standard chemotherapy: A new era? A meta-analysis of randomized controlled trials

11 p | 4 | 2

Metastatic lung adenocarcinoma with BRCA2 mutation and longstanding disease control on olaparib, developing triple negative breast adenocarcinoma with additional BRCA2 reversion mutation: A case report

5 p | 4 | 2

The prognostic value of Her4 receptor isoform expression in triple-negative and Her2 positive breast cancer patients

10 p | 7 | 0